Brief: Supernus Pharmaceuticals Q4 Revenue USD 46.4 Million Vs. IBES Estimate USD 155 Million
27/02/2024 21:06
Feb 27 (Reuters) - Supernus Pharmaceuticals Q4 adjusted operating earnings USD 47.1 million. * outlook FY revenue USD 580-620 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing